Alnylam Pharmaceuticals (ALNY) has announced positive Phase 3 results from the ILLUMINATE-A study of lumasiran for the treatment of primary hyperoxaluria type 1 …
This morning Alnylam Pharma (NASDAQ:ALNY) announced that it initiated a Phase 1/2 clinical trial for ALN-CC5 for complement-mediated diseases. Initial data is expected in …
